Itraconazole interferes in the pharmacokinetics of fuzuloparib in healthy volunteers
Author:
Funder
Capital Science and Technology Leading Talent Training Project
Beijing Hospitals Authority Ascent Plan
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
https://link.springer.com/content/pdf/10.1007/s00280-023-04536-5.pdf
Reference22 articles.
1. Wang L, Yang C, Xie C et al (2019) Pharmacologic characterization of fuzuloparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 110(3):1064–1075. https://doi.org/10.1111/cas.13947
2. Morales J, Li L, Fattah FJ et al (2014) Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit Rev Eukaryot Gene Expr 24:15–28
3. Michelena J, Lezaja A, Teloni F et al (2018) Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance. Nat Commun 9:2678
4. Lee A (2021) Fuzuloparib: first approval. Drugs 81(10):1221–1226. https://doi.org/10.1007/s40265-021-01541-x
5. Luo J, Dai X, Hu H et al (2020) Fuzuloparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials. J Cancer Res Clin Oncol 146(3):721–737. https://doi.org/10.1007/s00432-019-03097-6
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3